Effects of Probiotic Therapy in the Treatment of Periodontitis.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

41 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-12-01

Study Completion Date

2016-08-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effect of the probiotic therapy as an adjunct to non-surgical periodontal treatment in patients diagnosed with Generalized Chronic Periodontitis. Clinical study's hypothesis is that with the use of probiotic therapy, the standard treatment could be enhance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Probiotic Use in Chronic Periodontitis Patients

NCT02403960

Periodontitis

COMPLETED NA

Probiotics Effects to Initial Periodontal Treatment

NCT05408364

Chronic Periodontitis

COMPLETED NA

Administration of L. Paracasei 28.4 as an Adjunct to the Treatment of Periodontitis

NCT05107622

Periodontitis

UNKNOWN PHASE1/PHASE2

Impact of Non-surgical Periodontal Therapy on Oral and Gut Microbiome

NCT04580355

Microbial Colonization Periodontal Diseases Periodontal Inflammation

UNKNOWN PHASE4

Effects of Antibiotic Therapy on the Short and Long-term Results of Periodontitis Treatments

NCT05065034

Periodontitis, Adult

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Before the study begins, the selected individuals will be identified by a numeric code and will receive instructions regarding oral hygiene as well as supragingival scaling in all teeth. According to a random numeric table generated by a computer software, the study coordinator will allocate each patient into one of the following groups: Control (Scaling and Root Planing - SRP) or Test (SRP + probiotic therapy). The subjects (Test and Control groups) will receive lozenge containing/not containing. In the Test group, the lozenge will present Bifidobacterium lactis HN019 (HN019). Individuals will be instructed (immediately after the first session of mechanical instrumentation) to consume twice a day for 4 weeks by dissolving the lozenge before bedtime, and when wake up. They will also be instructed not to consume other probiotic product during the study. Clinical, immunological and microbiological parameters will be assessed at baseline (pre-intervention) and after completion of non-surgical periodontal therapy 30 and 90 days. All patients will receive detailed information regarding the study (goals, benefits and risks) according to the Term of Consent. The sample size was determined using the software Graphpad Statemate 2.0 (GraphPad Software, Inc., San Diego, CA, USA). The ideal sample size to ensure an 80% power in the statistical analysis of the data obtained in this study was calculated considering the differences of means and standard deviations between the test and control groups of the study by Vivekananda et al. (2010). The α value was set at 0.05. The average dropout of patients in our previous studies (approximately 20%) was also considered to calculate the sample size. Thus, a sample size of at least 30 patients was considered appropriate for this study. The normality and homoscedasticity of the data obtained will be checked. Comparisons within groups and among groups at different time intervals will be performed through parametric or non-parametric appropriate tests. The significance level will be set at 5% in all tests. All calculations will be performed by SPSS software (SPSS, Chicago IL, USA).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Periodontitis Probiotics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

According to a random numeric table generated by a computer software, the study coordinator will allocate each patient into one of the following groups: Control (Scaling and Root Planing - SRP) or Test (SRP + probiotic therapy). The subjects (Control group) will receive placebo lozenge. In the Test group, the lozenge will contain Bifidobacterium lactis HN019. Individuals will be instructed (immediately after the first session of mechanical instrumentation) to consume twice a day for 4 weeks by dissolving the lozenge before bedtime and when wake up. They will also be instructed not to consume other probiotic product during the study. Clinical, immunological and microbiological parameters will be assessed at baseline (pre-intervention) and after completion of non-surgical periodontal therapy 30 and 90 days.

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Periodontal clinical examination (pre- and post-intervention) will be conducted by a single trained and calibrated examiner, who will be blinded to the experimental groups of the study. The examiner will also be blinded to the microbiological and immunological evaluations. SRP procedures will be performed by specialist in Periodontics, trained for these purposes, who will also be blinded to the experimental groups of the study.

The coded lozenge will be given to the examiner, who will distribute them to the patients and will not have any access to information regarding the content of the lozenge. In addition, the patients will be blinded to the content of the lozenge and the treatment assignment during the study. The meaning of each code number will be revealed by the study coordinator only after conducting the statistical analysis of the experimental data.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo

Scaling root planning + two lozenge per day not containing Bifidobacterium animalis lactis HN019 for 30 days.

Group Type PLACEBO_COMPARATOR

Scaling root planning

Intervention Type PROCEDURE

Periodontal treatment

Placebo

Intervention Type OTHER

two lozenge per day not containing Bifidobacterium animalis lactis HN019

Probiotic

Scaling root planning + two lozenge per day containing Bifidobacterium animalis lactis HN019 (10x9 colony-forming units) for 30 days.

Group Type EXPERIMENTAL

Scaling root planning

Intervention Type PROCEDURE

Periodontal treatment

Probiotic

Intervention Type DIETARY_SUPPLEMENT

two lozenge per day containing Bifidobacterium animalis lactis HN019

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Scaling root planning

Periodontal treatment

Intervention Type PROCEDURE

Probiotic

two lozenge per day containing Bifidobacterium animalis lactis HN019

Intervention Type DIETARY_SUPPLEMENT

Placebo

two lozenge per day not containing Bifidobacterium animalis lactis HN019

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* More than 30 years old
* All patients must present good general health.
* Previously untreated periodontitis
* Minimum of 15 teeth

Exclusion Criteria

* Having received antibiotics for any purpose within 6 months prior to entering the study or the need for antibiotic coverage for dental treatment
* Pregnancy and nursing
* Acute oral lesions or necrotizing ulcerative periodontitis,
* A history of diabetes, rheumatic fever, liver or kidney disease, neurological deﬁciencies, immunological diseases or use of medication which may affect periodontal tissue, (phenytoin, cyclosporin, niﬁdepine, chronic use of non-steroidal anti-inﬂammatory drugs)
* Current smoker or former smoker

Minimum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No